ABSTRACT
Pleurotus ostreatus cv. Florida is one of the widely used edible mushroom. The polysaccharides from this mushrooms have been studied for antidiabetic potential; however, no efforts have been made to explore the potential of this mushroom to influence carbohydrate metabolizing enzymes viz. ?-amylase and ?-glucosidase. The present work was undertaken to investigate the inhibitory potential of Pleurotus ostreatus cv. Florida on enzymes ?-amylase and ?-glucosidase. Several concentrations of extracts were used to study inhibition of enzymatic activity of ?-amylase and ?-glucosidase. A dose dependent inhibitory effect on enzymes was observed. The current study, for the first time, uncovered ?-amylase and ?-glucosidase inhibitory potential of Pleurotus ostreatus cv. Florida. The study could be helpful to isolate and characterize compounds responsible for it.
ABSTRACT
Plant, mineral, and animal products have been utilized as medications from the beginning of time to cure a variety of ailments. Use of medicinal herbs to modulate immune function has a rich history. Natural products serve as the foundation for contemporary pharmaceutical ingredients. Immunomodulation alters an individual's immune system by interfering with its normal processes. Immunomodulators derived from natural sources have been extensively studied in order to modify the immune system and prevent illness. Berberine is an alkaloid has been identified for its anti-inflammatory properties. In animal studies, Berberine was found to demonstrate analgesic properties. The current work is aimed to explore the in silico interactions of Berberine with various chemokines and inflammatory pathways. Berberine was docked with TNF-?, IL-1?, IL-6, and NOs in this investigation. Docking study demonstrated notable interactions with these targets. The present research provides insight into the development of new compounds for immunomodulation and the management of inflammatory illnesses. More research on Berberine and related flavonoids is necessary to assess its safety. As a result, Berberine can be regarded as a candidate for the advancement of an immunomodulatory agent.
ABSTRACT
Background: Chemotherapy induced nausea and vomiting (CINV) remains one of the most common and debilitating complications of highly emetogenic chemotherapy (HEC). This study was undertaken to evaluate palanosetron against other 5-HT3 receptor antagonists in preventing delayed CINV with the aim of achieving complete response (CR) and improving quality of life (QoL).Methods: This was a prospective, observational study conducted on 75 histopathologically proven patients of squamous cell carcinoma of Head and Neck (H&N), who came to the Department of Radiation Oncology, Gandhi Medical College and Hamidia Hospital, Bhopal from January to December 2015. Standard protocol based chemotherapy containing highly emetogenic cisplatin based chemotherapy was administered to all the patients. For prevention of delayed chemotherapy induced nausea and vomiting all patients were prescribed oral 5-HT3 antagonists. Oral Ondansetron 4mg TDS was given to cohort 1, oral Granisetron 1 mg BD to cohort2 and oral Palanosetron 0.5mg OD was given to cohort 3. They were graded as complete response when they did not have complains of nausea and vomiting.Results: In Ondansetron, Granisetron and in Palanosetron cohort 29%, 53% and 98% patients had complete response.Conclusions: Palanosetron appears superior. Our study was conducted on handfull of patients and compared palanosetron against only two 5-HT3 receptor antagonists, so a larger study is suggested to establish the efficacy and better response of palanosetron.
ABSTRACT
Background: Cancer patients receiving chemotherapy have a high risk of malnutrition secondary to the disease and treatment, and majority of cancer patients suffer from different degrees of malnutrition, depending on tumour subtype, location, staging and treatment strategy. Early nutritional assessment can identify problems to help patients increase or maintain weight, improve their response to treatment, and reduce complications. This study aimed to determine the nutritional status of patients receiving chemotherapy. Methods: A prospective study was conducted among 447 subjects diagnosed with cancer of various sites and scheduled for three cycles of induction or adjuvant chemotherapy. Nutritional status of each subject was assessed based on nutritional parameters i.e. Anthropometric [BMI, MAMC, TSF, and MAC] and Biochemical [(Haemoglobin, Serum electrolytes and Albumin)] measurements before the initiation of chemotherapy, and follow-up assessment was performed on the completion of third cycle of chemotherapy. Results: In this study it has been found that 95% of subjects suffered from weight loss post chemotherapy. The't' test showed a significant decrease in TSF [t=4.8(p<0.01)], MAC [t=5.94 (p<0.01)] and MAMC, t=5.34(p<0.01) before and after 3 cycles of chemotherapy. Conclusion:The nutritional status assessment must be carried out on each patient at the beginning and during the treatment. The cancer patients are at high risk of malnutrition and associated comorbidities. K